Pfizer, J&J, and Merck Among T. Rowe Price’s Top Healthcare Stock Positions

Wall St. Watchdog reveals information regarding T. Rowe Price Associates, Inc.’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 282 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $24.865 billion.

  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 123,093,519 shares with a market value of $2,535,726,538. This comprised 0.81% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 127,249,949 shares with a market value of $2,249,779,137. This comprised 0.87% of the total portfolio. The net change in shares for this position over the two quarters is 4,156,430. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 25,121,920 shares with a market value of $1,671,110,034. This comprised 0.53% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 24,687,202 shares with a market value of $1,572,327,861. This comprised 0.6% of the total portfolio. The net change in shares for this position over the two quarters is -434,718. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 38,348,758 shares with a market value of $1,353,327,705. This comprised 0.43% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 41,075,424 shares with a market value of $1,343,166,396. This comprised 0.52% of the total portfolio. The net change in shares for this position over the two quarters is 2,726,666. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 16,551,890 shares with a market value of $998,410,000. This comprised 0.32% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 16,754,000 shares with a market value of $1,037,240,137. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 202,110. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 13,878,812 shares with a market value of $652,720,511. This comprised 0.21% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 14,434,992 shares with a market value of $924,705,552. This comprised 0.36% of the total portfolio. The net change in shares for this position over the two quarters is 556,180. About Company: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 10,384,693 shares with a market value of $619,862,311. This comprised 0.2% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 16,292,398 shares with a market value of $914,655,214. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 5,907,705. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 17,018,141 shares with a market value of $993,008,501. This comprised 0.32% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 16,176,037 shares with a market value of $889,034,979. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -842,104. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Thermo Fisher Scientific Inc. (NYSE:TMO): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 15,129,372 shares with a market value of $974,180,254. This comprised 0.31% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 16,651,891 shares with a market value of $843,251,750. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is 1,522,519. About Company: Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
  • Stryker Corp. (NYSE:SYK): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 16,857,502 shares with a market value of $989,366,769. This comprised 0.32% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 15,721,572 shares with a market value of $740,957,705. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is -1,135,930. About Company: Stryker Corporation develops, manufactures, and markets specialty surgical and medical products. The Company’s products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, T. Rowe Price Associates, Inc. reported holding 13,923,574 shares with a market value of $718,177,972. This comprised 0.23% of the total portfolio. On 09/30/2011, T. Rowe Price Associates, Inc. reported holding 16,005,504 shares with a market value of $738,173,827. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 2,081,930. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.

(Note: Data regarding T. Rowe Price Associates, Inc.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>